

# Libero Santarpia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/850404/publications.pdf>

Version: 2024-02-01

66  
papers

5,114  
citations

125106  
35  
h-index

139680  
61  
g-index

66  
all docs

66  
docs citations

66  
times ranked

10664  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the MAPK/RAS/RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 103-119.	1.5	740
2	miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Research and Treatment, 2016, 160, 439-446.	1.1	678
3	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, 2603-2614.	2.0	265
4	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 264-272.	3.0	203
5	A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. Clinical Cancer Research, 2015, 21, 1207-1214.	3.2	191
6	Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 278-284.	1.8	177
7	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 377-389.	12.5	164
8	Targeting microRNAs as key modulators of tumor immune response. Journal of Experimental and Clinical Cancer Research, 2016, 35, 103.	3.5	160
9	Missense Mutation in the Transcription Factor NKX2-5: A Novel Molecular Event in the Pathogenesis of Thyroid Dysgenesis. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1428-1433.	1.8	157
10	Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. International Journal of Cancer, 2016, 138, 87-97.	2.3	136
11	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 2015, 6, 37269-37280.	0.8	135
12	Prolyl isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Molecular Medicine, 2014, 6, 99-119.	3.3	130
13	Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 386-391.	1.8	120
14	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 2013, 12, 1679-1687.	1.3	109
15	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	1.1	106
16	Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treatment Reviews, 2013, 39, 541-550.	3.4	106
17	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. Journal of Thoracic Oncology, 2022, 17, 103-115.	0.5	89
18	Breast cancer assessment tools and optimizing adjuvant therapy. Nature Reviews Clinical Oncology, 2010, 7, 725-732.	12.5	83

#	ARTICLE	IF	CITATIONS
19	Uncovering the metabolomic fingerprint of breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1010-1020.	1.2	77
20	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. <i>Oncologist</i> , 2013, 18, 1063-1073.	1.9	75
21	A miRNA signature associated with human metastatic medullary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2013, 20, 809-823.	1.6	74
22	Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. <i>Cancer</i> , 2010, 116, 2974-2983.	2.0	70
23	Notch is a direct negative regulator of the DNA-damage response. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 417-424.	3.6	68
24	<i>TP53</i> mutation-correlated genes predict the risk of tumor relapse and identify <i>MPS1</i> as a potential therapeutic kinase in <i>TP53</i> -mutated breast cancers. <i>Molecular Oncology</i> , 2014, 8, 508-519.	2.1	59
25	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. <i>Cancer Research</i> , 2010, 70, 8852-8862.	0.4	58
26	The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors. <i>Endocrine Reviews</i> , 2010, 31, 578-599.	8.9	56
27	MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. <i>Endocrine-Related Cancer</i> , 2010, 17, F51-F75.	1.6	53
28	Homologies Between Proteins of <i>Borrelia burgdorferi</i> and Thyroid Autoantigens. <i>Thyroid</i> , 2004, 14, 964-966.	2.4	49
29	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , 2013, 15, R86.	2.2	44
30	Human Thyroid Autoantigens and Proteins of <i>Yersinia</i> and <i>Borrelia</i> Share Amino Acid Sequence Homology That Includes Binding Motifs to HLA-DR Molecules and T-Cell Receptor. <i>Thyroid</i> , 2006, 16, 225-236.	2.4	43
31	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. <i>Oncologist</i> , 2016, 21, 1063-1078.	1.9	41
32	AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. <i>Npj Breast Cancer</i> , 2016, 2, 16033.	2.3	41
33	High Resolution Array-Comparative Genomic Hybridization Profiling Reveals Deoxyribonucleic Acid Copy Number Alterations Associated with Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4367-4372.	1.8	39
34	RET TKI: Potential Role in Thyroid Cancers. <i>Current Oncology Reports</i> , 2012, 14, 97-104.	1.8	38
35	Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. <i>Human Pathology</i> , 2008, 39, 15-20.	1.1	37
36	Targeting the microRNA-regulating DNA damage/repair pathways in cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1667-1683.	1.4	36

#	ARTICLE	IF	CITATIONS
37	Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. <i>Molecular Carcinogenesis</i> , 2011, 50, 655-667.	1.3	35
38	Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-16.	0.6	34
39	Progress in nonviral gene therapy for breast cancer and what comes next?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 595-611.	1.4	32
40	The role of topoisomerase II $\pm$ and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. <i>Cancer Treatment Reviews</i> , 2009, 35, 662-667.	3.4	30
41	Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. <i>Human Pathology</i> , 2009, 40, 827-833.	1.1	28
42	Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. <i>Cytokine</i> , 2012, 59, 218-222.	1.4	26
43	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. <i>British Journal of Cancer</i> , 2018, 118, 1107-1114.	2.9	26
44	Lymphocytic Hypophysitis: Differential Diagnosis and Effects of High-Dose Pulse Steroids, Followed by Azathioprine, on the Pituitary Mass and Endocrine Abnormalities â€” Report of a Case and Literature Review. <i>Scientific World Journal</i> , The, 2010, 10, 126-134.	0.8	24
45	Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. <i>Head and Neck</i> , 2009, 31, 419-423.	0.9	23
46	Mosaicism in von Hippel-Lindau disease: an event important to recognize. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1408-1415.	1.6	22
47	Four Patients with Cutaneous Metastases from Medullary Thyroid Cancer. <i>Thyroid</i> , 2008, 18, 901-905.	2.4	20
48	Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 194.	1.8	18
49	Adjuvant systemic treatment for individual patients with triple negative breast cancer. <i>Breast</i> , 2011, 20, S135-S141.	0.9	14
50	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. <i>Breast</i> , 2012, 21, 336-342.	0.9	12
51	PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance. <i>Cancer Investigation</i> , 2008, 26, 1044-1051.	0.6	11
52	Triple negative breast cancer: a heterogeneous subgroup denned by what it is not. <i>European Journal of Cancer</i> , 2011, 47, S370-S372.	1.3	11
53	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. <i>Journal of Cancer</i> , 2017, 8, 1045-1052.	1.2	9
54	Targeted Therapy for Endocrine Cancer: The Medullary Thyroid Carcinoma Paradigm. <i>Endocrine Practice</i> , 2009, 15, 597-604.	1.1	7

#	ARTICLE	IF	CITATIONS
55	Germline Mutation of von Hippel-Lindau (VHL) Gene 695 G>A (R161Q) in a Patient with a Peculiar Phenotype with Type 2C VHL Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 198-202.	1.8	5
56	Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 301.	0.4	5
57	Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers. <i>Current Pharmaceutical Design</i> , 2013, 19, 864-882.	0.9	5
58	Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. <i>Future Oncology</i> , 2011, 7, 173-186.	1.1	4
59	Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers. <i>Current Pharmaceutical Design</i> , 2013, 19, 864-82.	0.9	3
60	A Novel Von Hippel-Lindau Point Mutation Presents as Apparently Sporadic Pheochromocytoma. <i>Cancer Investigation</i> , 2008, 26, 642-646.	0.6	2
61	Predictive molecular markers of anthracycline effectiveness in early breast cancer. <i>European Journal of Cancer, Supplement</i> , 2011, 9, 16-21.	2.2	1
62	Erratum to "Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma" [Hum Pathol 40 (2009) 827-833]. <i>Human Pathology</i> , 2009, 40, 1212.	1.1	0
63	Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents. <i>Current Breast Cancer Reports</i> , 2011, 3, 24-33.	0.5	0
64	E16. Clinical implications of microRNAs in breast cancer. <i>European Journal of Cancer</i> , 2012, 48, S32-S34.	1.3	0
65	miRNAs in medullary thyroid carcinoma: when will they be relevant to the clinic?. <i>International Journal of Endocrine Oncology</i> , 2014, 1, 7-10.	0.4	0
66	Circulating Nucleic Acids (RNA/DNA) in Breast Cancer. , 2016, , 235-256.		0